Due to their low cost and environmentally friendly nature, plant extracts based methods have gained significant popularity among researchers for the synthesis of metallic nanoparticles. Herein, green synthesis of silver nanoparticles was performed using the aqueous solution of Ziziphus mauritiana leaves extract (ZM-LE) as a bio-reducing agent. The as-obtained silver nanoparticles were characterized by using UV-Vis spectroscopy, XRD (X-ray diffraction), TEM (transmission electron microscopy), and FT-IR (Fourier-transform infrared spectroscopy). In addition, the effects of the concentrations of the leaves extract, silver nitrate, and the temperature on the preparation of nanoparticles were also investigated. In order to determine the nature of secondary metabolites present in leaves extract, a preliminary investigation of phytoconstituents was carried out using different methods including Folin-Ciocalteu and AlCl3 methods. The results have indicated the presence of a considerable amount of phenolic and flavonoid contents in the leaves extract, which are believed to be responsible for the reduction of silver ions and stabilization of resulting nanoparticles. Indeed, the FT-IR spectrum of silver nanoparticles also confirmed the presence of residual phytomolecules of leaves extract as stabilizing ligands on the surface of nanoparticles. The antibacterial properties of as-obtained silver nanoparticles were tested against various bacterial strains including Escherichia coli, Staphylococcus aureus, Pseudomonas aeruginosa, and Bacillus subtilis. The nanoparticles strongly inhibited the growth of S. aureus with a minimum inhibitory concentration (MIC) of 2.5 μg/ml and moderately inhibited the growth of E. coli with a MIC of 5 μg/ml.
1 September 2017 in Saudi Journal of Biological Sciences
Several reports document the role of tumor necrosis factor alpha (TNF-α) and lipid metabolism in the context of acute inflammation as a causative factor in obesity-associated insulin resistance and as one of the causative parameter of type 2 diabetes mellitus (T2DM). Our aim was to investigate the association between -308G/A and -238G/A polymorphisms located in the promoter region of the TNF-α gene in T2DM in the Indian population with bioinformatics analysis of TNF-α protein networking with an aim to find new target sites for the treatment of T2DM. Demographics of 100 diabetes patients and 100 healthy volunteers were collected in a structured proforma and 3 ml blood samples were obtained from the study group, after approval of Institutional Ethics Committee of the hospital (IEC). The information on clinical parameters was obtained from medical records. Genomic DNA was extracted; PCR-RFLP was performed using TNF-α primers specific to detect the presence of SNPs. Various bioinformatics tools such as STRING software were used to determine its network with other associated genes. The PCR-RFLP studies showed that among the -238G/A types the GG genotype was 87%, GA genotype was 12% and AA genotype was 1%. Almost a similar pattern of results was obtained with TNF-α -308G/A polymorphism. The results obtained were evaluated statistically to determine the significance. By constructing TNF-α protein interaction network we could analyze ontology and hubness of the network to identify the networking of this gene which may influence the functioning of other genes in promoting T2DM. We could identify new targets in T2DM which may function in association with TNF-α. Through hub analysis of TNF-α protein network we have identified three novel proteins RIPK1, BIRC2 and BIRC3 which may contribute to TNF-mediated T2DM pathogenesis. In conclusion, our study indicated that some of the genotypes of TNF-α -308G/A, -238G/A were not significantly associated to type 2 diabetes mellitus, but TNF-α -308G/A polymorphism was reported to be a potent risk factor for diabetes in higher age (>45) groups. Also, the novel hub proteins may serve as new targets against TNF-α T2DM pathogenesis.
Alterations in cell cycle regulating proteins are a key characteristic in neoplastic proliferation of lymphoblast cells in patients with Acute Lymphoblastic Leukemia (ALL). The aim of our study was to investigate whether the routinely administered ALL chemotherapeutic agents would be able to bind and inhibit the key deregulated cell cycle proteins such as - Cyclins E1, D1, D3, A1 and Cyclin Dependent Kinases (CDK) 2 and 6. We used Schrödinger Glide docking protocol to dock the chemotherapeutic drugs such as Doxorubicin and Daunorubicin and others which are not very common including Clofarabine, Nelarabine and Flavopiridol, to the crystal structures of these proteins. We observed that the drugs were able to bind and interact with cyclins E1 and A1 and CDKs 2 and 6 while their docking to cyclins D1 and D3 were not successful. This binding proved favorable to interact with the G1/S cell cycle phase proteins that were examined in this study and may lead to the interruption of the growth of leukemic cells. Our observations therefore suggest that these drugs could be explored for use as inhibitors for these cell cycle proteins. Further, we have also highlighted residues which could be important in the designing of pharmacophores against these cell cycle proteins. This is the first report in understanding the mechanism of action of the drugs targeting these cell cycle proteins in leukemia through the visualization of drug-target binding and molecular docking using computational methods.